Abstract
Primary adenoid cystic carcinoma (ACC) of the upper anterior mediastinum is a rare clinical entity that often mimics thyroid gland tumors, complicating diagnosis and management. We present the case of a 47-year-old female who underwent gross surgical resection followed by adjuvant chemotherapy and radiotherapy. While local control was maintained for three years, the patient eventually developed distant lung metastases, highlighting the aggressive nature of this malignancy.
The Diagnostic Challenge: A Masquerade
Adenoid cystic carcinoma typically originates in the salivary glands but can rarely arise in the respiratory tract. When located in the upper anterior mediastinum, its proximity to the thyroid gland often leads to clinical and radiographic misidentification as a primary thyroid tumor.
Standard thyroid malignancies, such as papillary or medullary carcinoma, follow distinct treatment protocols. Misdiagnosing ACC as a thyroid tumor can result in suboptimal surgical strategies. This case emphasizes the necessity of a rigorous diagnostic roadmap, particularly when imaging shows a mass adherent to both the trachea and the thyroid.
Case Presentation and Management
A 47-year-old female presented with swallowing discomfort. Imaging revealed a mass in the upper anterior mediastinum compressing the trachea and esophagus. The patient underwent a complex surgical procedure including total thyroidectomy, upper mediastinal tumor resection, and recurrent laryngeal nerve exploration.
Post-operative management included:
- Adjuvant Radiotherapy: Intensity-modulated radiation therapy (IMRT) delivering 70 Gy to the primary tumor bed.
- Chemotherapy: A regimen of Cisplatin and Docetaxel was initiated but discontinued after one cycle due to intolerable gastrointestinal side effects.
Key Diagnostic Insights: The IHC "Fingerprint"
The definitive diagnosis of ACC relies on histopathology—specifically the identification of "cribriform" growth patterns—and a comprehensive immunohistochemical (IHC) panel. Differentiating ACC from primary thyroid tumors is critical; while thyroid cancers typically express Thyroglobulin (Tg) and Thyroid Transcription Factor-1 (TTF-1), this tumor was negative for both.
Instead, the tumor showed strong positivity for CD117 (c-KIT), p63, and SMA. This IHC profile serves as a diagnostic "fingerprint" for ACC, distinguishing it from common thyroid pathologies.
Clinical Outcomes and Future Directions
The patient achieved excellent local control, with no recurrence at the primary site for three years. However, the "indolent but relentless" nature of ACC was confirmed when multiple lung nodules appeared two years post-treatment. This underscores that ACC is often a systemic disease requiring long-term surveillance.
While 5-year survival rates for ACC are relatively high (78–90%), 15-year survival drops significantly (35–69%). Future therapeutic strategies may need to move beyond traditional chemotherapy toward targeted molecular therapies, such as those focusing on MYB-NFIB gene translocations or VEGFR2/EGFR inhibitors, to manage distant metastatic disease effectively.
Summary updated